Scope Fluidics S.A. is a biotechnology company focused on advancing medical diagnostics through innovative microfluidic technologies. The company has developed the BacterOMIC system, which is designed to assess the drug susceptibility of microorganisms, addressing the critical issue of antibiotic resistance. This system provides comprehensive insights into the resistance mechanisms of bacteria and their sensitivity to various antibiotics, enabling healthcare providers to implement effective therapies, reduce complications from infections, and lower treatment costs. Additionally, Scope Fluidics has created the PCR|ONE system, which facilitates rapid diagnosis of diseases caused by bacterial and viral agents, further enhancing the speed and accessibility of medical diagnostics.

The operational model of Scope Fluidics emphasizes the development of solutions that meet pressing healthcare needs by combining creativity with engineering expertise. The company engages interdisciplinary teams to transform innovative concepts into viable products, ensuring that these solutions are not only effective but also cost-efficient and manufacturable. By establishing strategic partnerships with global operators in the medical diagnostics market, Scope Fluidics aims to maximize the impact of its technologies on healthcare, ultimately contributing to improved patient outcomes and a healthier society.

Poland

Scope Fluidics group is  a hub for medtech startups. Scope Fluidics focuses on global challenges in health and accelerates ideas into products by providing legal, financial, and infrastructural resources, as well as critical know‑how. Scope Fluidics provides Curiosity  Diagnostics and Bacteromic with a stimulating environment in which engineers and scientists cooperate with clinical experts to deliver groundbreaking medical products.

Scope Fluidics

Company Details